* Kiora Pharmaceuticals Inc is expected to show no change in quarterly revenue when it reports results on March 21 (estimated) for the period ending December 31 2023
*
* LSEG's mean analyst estimate for Kiora Pharmaceuticals Inc is for a loss of 42 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Kiora Pharmaceuticals Inc is $3.00, above its last closing price of $0.60.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.34 -0.35 -0.89 Missed -151.9
Jun. 30 2023 -0.74 -1.07 -0.79 Beat 25.9
Mar. 31 2023 -1.71 -1.68 -1.00 Beat 40.7
Dec. 31 2022 -2.23 -2.46 -1.76 Beat 28.6
Sep. -3.68 -3.83 -6.03 Missed -57.3
30 2022
Jun. 30 2022 -8.00 -8.00 -7.20 Beat 10
Mar. 31 2022 -9.40 -9.40 -10.80 Missed -14.9
Dec. 31 2021 -9.20 -26.47 Missed -187.7
This summary was machine generated March 19 at 12:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments